Last reviewed · How we verify

AK104 plus Carboplatin and Pemetrexed

Akeso · Phase 1 active Small molecule

AK104 plus Carboplatin and Pemetrexed is a Small molecule drug developed by Akeso. It is currently in Phase 1 development.

At a glance

Generic nameAK104 plus Carboplatin and Pemetrexed
SponsorAkeso
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AK104 plus Carboplatin and Pemetrexed

What is AK104 plus Carboplatin and Pemetrexed?

AK104 plus Carboplatin and Pemetrexed is a Small molecule drug developed by Akeso.

Who makes AK104 plus Carboplatin and Pemetrexed?

AK104 plus Carboplatin and Pemetrexed is developed by Akeso (see full Akeso pipeline at /company/akeso).

What development phase is AK104 plus Carboplatin and Pemetrexed in?

AK104 plus Carboplatin and Pemetrexed is in Phase 1.

Related